Avaleht › Müeloom › Washington › Seattle
Müeloom kliinilised uuringud linnas Seattle, WA
22 uuringut haiguse Müeloom jaoks otsivad osalejaid linnas Seattle ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
VärbamineFaas 3
- Research Site, Seattle
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
VärbamineFaas 1/2
- University of Washington, Seattle
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
VärbamineFaas 2
- University of Washington, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
VärbamineFaas 2
- Swedish Cancer Institute, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
VärbamineFaas 3
- Fred Hutchinson Cancer Research Center, Seattle
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
VärbamineFaas 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
VärbamineVaatlusuuring
- Fred Hutchinson, Seattle
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 2
- Fred Hutchinson Cancer Center, Seattle
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
VärbamineFaas 3
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · 17 mi kaugusel
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
VärbamineFaas 1/2
- Research Site, Seattle
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
VärbamineFaas 3
- Research Site, Seattle
- Research Site, Seattle
Selinexor and Backbone Treatments of Multiple Myeloma Patients
VärbamineFaas 1/2
- Fred Hutch Cancer Center, Seattle
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
VärbamineFaas 1
- VA Puget Sound Health Care System, Seattle
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
VärbamineFaas 3
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- ja veel 1
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1
- Fred Hutchinson Cancer Center, Seattle
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1
- Swedish Medical Center - Seattle /ID# 268052, Seattle
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
VärbamineFaas 1/2
- Swedish Cancer Institute, Seattle
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
VärbamineFaas 1
- Swedish Medical Center, Seattle
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Värbamine
- University of Washington, Seattle
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Värbamine
- University of Washington, Seattle
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
VärbamineVaatlusuuring
- All4Cure, Seattle
Müeloom uuringud teistes linnades
- New York City, NY60 uuringut
- Boston, MA42 uuringut
- Atlanta, GA41 uuringut
- Houston, TX38 uuringut
- Durham, NC37 uuringut
- Nashville, TN32 uuringut
- Denver, CO27 uuringut
- Rochester, MN24 uuringut
- St. Louis, MO24 uuringut
- Columbus, OH24 uuringut
- Baldwin Park, CA23 uuringut
- Chicago, IL22 uuringut
Muud uuringud linnas Seattle
- Mitteväikerakuline kopsuvähk53 uuringut
- Vähk (kõik liigid)49 uuringut
- Eesnäärmevähk42 uuringut
- Äge müeloidne leukeemia40 uuringut
- Rinnavähk39 uuringut
- Metastaatiline vähk39 uuringut
- Käär- ja pärasoolevähk34 uuringut
- Kopsuvähk33 uuringut
- Munasarjavähk30 uuringut
- Müelodüsplastilised sündroomid21 uuringut
- Äge lümfoblastne leukeemia21 uuringut
- Põievähk21 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.